Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/johnson--johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-congress-302285418.html

PR NEWSWIRE
24 Oct 2024

https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-seeks-U.S.-FDA-approval-of-SPRAVATO-esketamine-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression/default.aspx

PRESS RELEASE
22 Jul 2024

https://www.accesswire.com/viewarticle.aspx?id=876673&lang=en

ACCESSWIRE
12 Jun 2024
Johnson & Johnson 1Q Results
Johnson & Johnson 1Q Results

20 May 2024

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2024-05-20/johnson-amp-johnson-1q-results/?widget=listSection

CONTRACT PHARMA
20 May 2024

https://www.globenewswire.com/news-release/2023/10/08/2756367/0/en/New-Safety-Data-Suggests-SPRAVATO-Esketamine-Nasal-Spray-is-More-Tolerable-and-Effective-Compared-to-Quetiapine-Extended-Release-XR-in-Adults-with-Treatment-resistant-Major-Depress.html

GLOBENEWSWIRE
08 Oct 2023

https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-esketamine-hydrochloride-49242.pdf

FDA
25 Apr 2023